The brain's receptors: a field guide

How receptors turn a neurotransmitter into an effect: the two designs, the main families, what each does, and the medicines that act on them.

Vicente19 min read

A neurotransmitter has no meaning until a receptor reads it. The receptor decides whether a signal excites or inhibits, whether it lasts a millisecond or a minute, and which cells respond at all.

This is why one transmitter can do opposite things. Acetylcholine contracts skeletal muscle and slows the heart. Dopamine starts a movement through one receptor and restrains it through another. The difference is the receptor.

Receptors are also where medicine is most precise. A transporter or enzyme drug changes the level of a transmitter everywhere. A receptor drug can change one of its effects and leave the others alone.

#How this list was prioritized

The brain has several hundred receptor types. This post covers the families that matter most, ranked by impact: how much of brain function runs through them, and how many medicines act on them.

  1. Glutamate and GABA receptors come first. They carry nearly all fast signalling.
  2. Dopamine, serotonin, adrenergic and acetylcholine receptors come next. Most psychiatric medicines act here.
  3. Histamine and opioid receptors follow, then a short list of others worth knowing.

Each section is self-contained and follows the same order: the subtypes, how they work, what they do, what goes wrong, and the medicines that act on them.

This post is one of three. The companion posts cover the neurotransmitters these receptors read and the transporters that clear them.

#The two designs

Every neurotransmitter receptor is one of two kinds. Knowing which kind tells you its speed, its duration and how drugs can act on it.

[diagram]
Ion-channel receptors act in milliseconds; G-protein receptors reset the cell
Ion-channel receptor
G-protein receptor
Transmitter binds
the receptor is itself a channel
Pore opens
within a millisecond
Ions flow
the cell's voltage shifts at once
Transmitter binds
the receptor has no pore
G protein switches on
Gs, Gi or Gq sets the direction
Second messengers spread
channels, enzymes and genes change
Fast, brief and local on the left: AMPA, NMDA, GABA-A, nicotinic. Slow, lasting and amplified on the right: dopamine, muscarinic, opioid and most serotonin receptors.
Transmitter binds leads to Pore opens
Pore opens leads to Ions flow
Transmitter binds leads to G protein switches on
G protein switches on leads to Second messengers spread
Ion-channel receptors (ionotropic)G-protein receptors (metabotropic)
What it isA channel that opens when transmitter bindsA sensor that activates a G protein inside the cell
SpeedUnder a millisecondTenths of a second to minutes
EffectIons flow and voltage changes at onceSecond messengers change channels, enzymes and gene activity
AmplificationNone: one receptor, one channelLarge: one receptor activates many G proteins
ExamplesAMPA, NMDA, GABA-A, nicotinic, 5-HT3, glycineAll dopamine, adrenergic, muscarinic, opioid and most serotonin receptors

#The three G proteins

A G-protein receptor's effect depends on which G protein it couples to. Three families cover nearly every receptor in this post.

G proteinWhat it does inside the cellNet effectReceptors that use it
GsRaises cAMPActivatingD1, D5, beta-adrenergic, H2, 5-HT4, 5-HT6, 5-HT7
GiLowers cAMP, opens potassium channels, closes calcium channelsQuietingD2, D3, D4, alpha-2, 5-HT1, GABA-B, opioid, M2, M4, CB1
GqReleases calcium from internal storesActivatingAlpha-1, 5-HT2, M1, M3, M5, H1

#How drugs act on a receptor

TermMeaningExample
AgonistActivates the receptor fullyPramipexole at dopamine D2 and D3
Partial agonistActivates it weakly. Raises low signalling and caps high signalling.Aripiprazole at D2
AntagonistOccupies the receptor and blocks the transmitter, with no effect of its ownHaloperidol at D2
Inverse agonistReduces the receptor's activity below its resting levelPimavanserin at 5-HT2A
Allosteric modulatorBinds a second site and turns the transmitter's effect up or downBenzodiazepines at GABA-A

#Where a receptor sits

  • Postsynaptic receptors sit on the receiving cell and carry the signal forward.
  • Autoreceptors sit on the releasing cell and detect its own transmitter. They act as a brake on further release.
  • Extrasynaptic receptors sit away from synapses and respond to low background levels of transmitter.

#Receptors adapt

Receptor numbers are not fixed. Sustained stimulation makes cells remove receptors or uncouple them. Sustained blockade makes cells add more. This adaptation underlies tolerance, withdrawal effects when a medicine is stopped abruptly, and the delayed onset of many psychiatric treatments.

#Map at a glance

Every receptor family in this post, in the order it appears. Rows are sorted by impact, highest first.

TransmitterReceptorDesignMain effectMedicines that act on it
GlutamateAMPAIon channelFast excitationPerampanel
GlutamateNMDAIon channelLearning, plasticityEsketamine, memantine
GlutamatemGluR1 to mGluR8G proteinFine-tunes excitationNone approved
GABAGABA-AIon channelFast inhibitionBenzodiazepines, zolpidem, propofol, zuranolone
GABAGABA-BG protein, GiSlow inhibitionBaclofen
DopamineD1, D5G protein, GsPromotes action, working memoryNone selective in wide use
DopamineD2, D3, D4G protein, GiRestrains action; autoreceptorAntipsychotics, pramipexole, aripiprazole
Serotonin5-HT1AG protein, GiCalming; autoreceptorBuspirone
Serotonin5-HT1B, 5-HT1DG protein, GiReduces transmitter releaseTriptans
Serotonin5-HT2AG protein, GqExcites cortexSecond-generation antipsychotics, pimavanserin
Serotonin5-HT3Ion channelNausea, gut reflexesOndansetron
NoradrenalineAlpha-1G protein, GqArousal, vessel constrictionPrazosin
NoradrenalineAlpha-2G protein, GiBrake on release; prefrontal focusClonidine, guanfacine
NoradrenalineBetaG protein, GsHeart rate, emotional memoryPropranolol
AcetylcholineNicotinicIon channelMuscle contraction, attentionVarenicline
AcetylcholineMuscarinic M1 to M5G proteinMemory, parasympathetic controlXanomeline; many anticholinergics
HistamineH1G protein, GqWakefulnessAntihistamines
HistamineH3G protein, GiAutoreceptorPitolisant
Opioid peptidesMu, delta, kappaG protein, GiPain relief, rewardOpioid pain medicines, naloxone, buprenorphine
AdenosineA1, A2AG proteinSleep pressureCaffeine blocks both
OrexinOX1, OX2G proteinStable wakefulnessSuvorexant, lemborexant, daridorexant
MelatoninMT1, MT2G protein, GiBody clock timingMelatonin, ramelteon

#Glutamate receptors

Glutamate receptors carry the brain's excitation and store its memories. Two ion-channel types do the main work as a pair: AMPA receptors pass the signal, and NMDA receptors decide whether the synapse should be strengthened.

#The subtypes

ReceptorDesignLets inRole
AMPAIon channelSodiumFast excitation at nearly every excitatory synapse
NMDAIon channelSodium and calciumDetects coincident activity and triggers plasticity
KainateIon channelSodiumAdjusts release and excitability; least understood
mGluR1, mGluR5G protein, GqRaise excitability, on the receiving cell
mGluR2, mGluR3G protein, GiBrake on glutamate release, on the sending cell
mGluR4, 6, 7, 8G protein, GiBrake on release; mGluR6 is used in the retina

#How the AMPA and NMDA pair works

  1. Glutamate binds both receptors.
  2. The AMPA receptor opens at once and excites the cell.
  3. The NMDA receptor stays blocked by a magnesium ion sitting in its pore.
  4. If the cell is already excited enough, the magnesium is pushed out and the NMDA receptor opens.
  5. Calcium enters and signals the cell to add more AMPA receptors to that synapse.

The NMDA receptor therefore opens only when sending and receiving cells are active together. A synapse with more AMPA receptors responds more strongly next time. This is long-term potentiation, the best-studied cellular basis of learning.

The NMDA receptor also needs a second molecule, glycine or D-serine, bound at a separate site before it can open.

#When it goes wrong

  • Excitotoxicity. Prolonged NMDA receptor opening admits too much calcium and kills neurons. This occurs in stroke and brain injury.
  • Anti-NMDA receptor encephalitis. Antibodies remove NMDA receptors from the cell surface. Patients develop psychosis, memory loss, seizures and movement disorders, and usually recover with immune treatment.
  • Schizophrenia. Reduced NMDA receptor function is a leading model, supported by genetics and by the encephalitis above.
  • Developmental disorders. Mutations in NMDA receptor genes cause epilepsy and intellectual disability.

#Medicines

  • Esketamine blocks the NMDA receptor pore. It relieves treatment-resistant depression within hours to days, far faster than standard antidepressants.
  • Dextromethorphan with bupropion is an oral NMDA receptor blocker approved for depression.
  • Memantine blocks the pore weakly and briefly, which dampens excess activity while sparing normal signalling. It is used in Alzheimer's disease.
  • Perampanel blocks AMPA receptors and is used in epilepsy.

Drugs acting on metabotropic glutamate receptors have been tested in schizophrenia and fragile X syndrome. None has succeeded in large trials.

#GABA receptors

GABA receptors are the brain's inhibition. GABA-A is the most heavily medicated receptor in the brain: sedatives, sleep medicines, anaesthetics and many anti-seizure drugs all act on it.

#The two types

GABA-AGABA-B
DesignIon channelG protein, Gi
Lets throughChloride, inwardOpens potassium channels, closes calcium channels
SpeedMillisecondsHundreds of milliseconds
EffectHolds the cell below its firing thresholdSlow, lasting inhibition and less transmitter release
Main medicineBenzodiazepinesBaclofen

#GABA-A: a receptor built from parts

A GABA-A receptor is assembled from five subunits chosen from 19 possible kinds. The mix determines where it sits, how it behaves and which drugs affect it.

Subunit presentWhereLinked effect
Alpha-1Throughout the brain, at synapsesSedation
Alpha-2, alpha-3Amygdala, cortex, spinal cordRelief of anxiety, muscle relaxation
Alpha-5HippocampusMemory impairment
DeltaOutside synapsesSteady background inhibition; sensitive to neurosteroids

This is why the search for an anxiety medicine without sedation has focused on drugs that prefer alpha-2 and alpha-3.

#How the main drugs act

None of these opens the receptor in the normal way. Each binds its own site and changes how the receptor responds to GABA.

  • Benzodiazepines make the channel open more often when GABA is present. They do little without GABA, which limits their effect when taken alone.
  • Zolpidem and related sleep medicines bind the same site but prefer alpha-1 receptors.
  • Barbiturates and propofol hold the channel open longer and, at high doses, open it without GABA. This is why they can produce anaesthesia.
  • Neurosteroids such as zuranolone act on synaptic and extrasynaptic receptors. They are used for postpartum depression.
  • Flumazenil blocks the benzodiazepine site and reverses benzodiazepine effects.

#When it goes wrong

  • Epilepsy. Mutations in GABA-A subunit genes cause several inherited epilepsies.
  • Tolerance and dependence. With weeks of daily benzodiazepine use, receptors adapt. Stopping abruptly can cause rebound anxiety, insomnia and seizures, so doses are reduced gradually.
  • Postpartum depression. Levels of the natural neurosteroid allopregnanolone fall sharply after birth. This is the reasoning behind neurosteroid treatment.

#GABA-B

GABA-B receptors sit on both sides of the synapse. On the sending side they reduce transmitter release. On the receiving side they produce a slow inhibition. Baclofen activates them and is used to relieve spasticity.

#Dopamine receptors

Dopamine has five receptors in two families with opposite effects. The D2 receptor is the central target in the treatment of psychosis: every established antipsychotic acts on it.

#The two families

FamilyMembersG proteinEffect on the cellMainly found in
D1-likeD1, D5GsActivatingStriatum, prefrontal cortex
D2-likeD2, D3, D4GiQuietingStriatum, limbic areas, pituitary; D4 in cortex

#What they do

  • Movement: go and no-go. The striatum has two output pathways. The direct pathway carries D1 receptors and promotes action. The indirect pathway carries D2 receptors and suppresses action. Dopamine excites the first and quiets the second, so it favours movement through both.
  • Working memory. Prefrontal D1 receptors hold information in mind. Function is best at moderate stimulation and falls off with too little or too much.
  • Self-regulation. D2 autoreceptors on dopamine neurons slow firing and release when dopamine rises.
  • Motivation. D3 receptors are concentrated in limbic parts of the striatum that handle reward.
  • Hormones and nausea. D2 receptors in the pituitary hold back prolactin. D2 receptors in the brainstem trigger vomiting.

#D2 and antipsychotics

The clinical strength of the older antipsychotics tracks how tightly they bind D2. Imaging studies then defined a working range.

Share of D2 receptors blockedWhat is typically seen
Below about 60%Often too little antipsychotic effect
About 65% to 80%Antipsychotic effect
Above about 80%Stiffness, tremor, restlessness and raised prolactin become likely

These side effects follow from the map above. Blocking striatal D2 removes dopamine's support for movement. Blocking pituitary D2 releases prolactin.

Clozapine is the exception. It is the most effective antipsychotic for treatment-resistant illness and works at lower D2 occupancy, so D2 blockade is not the whole story.

#Medicines

MedicineActionUsed for
Haloperidol, risperidone, olanzapine and othersBlock D2Psychosis, mania
Aripiprazole, brexpiprazole, cariprazinePartly activate D2 and D3Psychosis, mania, add-on in depression
Pramipexole, ropiniroleActivate D2 and D3Parkinson's disease, restless legs
MetoclopramideBlocks D2 in the gut and brainstemNausea

#When it goes wrong

  • Tardive dyskinesia. Years of D2 blockade can produce involuntary movements, thought to reflect receptors becoming oversensitive.
  • Impulse control problems. D2 and D3 agonists can cause compulsive gambling, shopping or eating in some patients.
  • Parkinson's disease. With dopamine lost, the no-go pathway dominates and movement becomes slow and hard to start.

#Serotonin receptors

Serotonin has the largest receptor family of any transmitter: at least 14 types in seven groups. This is why raising serotonin everywhere, as reuptake blockers do, produces so many different effects, wanted and unwanted.

#The receptors that matter most

ReceptorDesignWhereWhat it doesMedicines
5-HT1AG protein, GiRaphe nuclei as autoreceptor; hippocampus, cortexSlows serotonin neurons; calms receiving cellsBuspirone partly activates it
5-HT1B, 5-HT1DG protein, GiNerve terminals, cranial blood vesselsReduces transmitter releaseTriptans activate them
5-HT2AG protein, GqCortex, especially pyramidal neuronsExcites cortical cells; shapes perceptionSecond-generation antipsychotics block it; pimavanserin
5-HT2CG protein, GqHypothalamus, limbic areasReduces appetite; restrains dopamine releaseBlocked by olanzapine and mirtazapine
5-HT3Ion channelBrainstem vomiting centre, gut nervesTriggers nausea and vomitingOndansetron blocks it
5-HT4G protein, GsGut, hippocampusSpeeds gut movementPrucalopride activates it
5-HT6, 5-HT7G protein, GsCortex, hippocampus, thalamusCognition, body clockNone in wide use

#Reading side effects from the map

A reuptake blocker raises serotonin at every receptor at once. Most early side effects trace to particular ones.

EffectReceptor most involved
Nausea5-HT3
Early restlessness and poor sleep5-HT2A, 5-HT2C
Sexual side effects5-HT2A, 5-HT2C
Weight gain with olanzapine or mirtazapineBlockade of 5-HT2C, with H1

Medicines that block some of these receptors while raising serotonin avoid some of these effects. Mirtazapine blocks 5-HT2 and 5-HT3 receptors, and causes little nausea or sexual dysfunction.

#Why antidepressants take weeks

One long-standing explanation involves the 5-HT1A autoreceptor. When a reuptake blocker raises serotonin, autoreceptors on raphe neurons detect it and slow those neurons down. Over two to four weeks the autoreceptors become less sensitive and firing recovers. Slower changes in brain plasticity also contribute.

#When it goes wrong, and current research

  • Psychosis in Parkinson's disease. Pimavanserin reduces it by acting on 5-HT2A, without blocking dopamine receptors.
  • Migraine. Triptans stop attacks through 5-HT1B and 5-HT1D.
  • Heart valves. Long-term activation of 5-HT2B receptors damages heart valves. Several older medicines were withdrawn for this reason, and new drugs are screened against it.
  • Clinical trials. Compounds that activate 5-HT2A are being studied under medical supervision for depression. They are not approved treatments in most countries.

#Adrenergic receptors

Adrenergic receptors read noradrenaline in the brain and both noradrenaline and adrenaline in the body. Three families do three different jobs, and each uses a different G protein.

#The three families

FamilyG proteinIn the brainIn the body
Alpha-1GqRaises arousal and alertnessNarrows blood vessels, raises blood pressure
Alpha-2GiBrake on noradrenaline release; strengthens prefrontal focusLowers sympathetic outflow, heart rate and blood pressure
Beta (1, 2, 3)GsStrengthens memory for emotional eventsBeta-1 speeds the heart; beta-2 opens the airways

#What they do

  • Alpha-2 has two roles. On noradrenaline neurons it is the autoreceptor that slows release. On prefrontal neurons it strengthens the connections that hold information in working memory.
  • The level decides which receptor wins. Moderate noradrenaline mainly engages alpha-2 receptors, which supports focus. High noradrenaline during stress also engages alpha-1 and beta receptors, which weaken prefrontal control and favour fast, habitual responses.
  • Beta receptors tag memories. Noradrenaline acting on beta receptors in the amygdala makes emotionally charged events easier to remember.

#Medicines

MedicineActionUsed for
Guanfacine, clonidineActivate alpha-2ADHD, high blood pressure
PrazosinBlocks alpha-1High blood pressure; trauma-related nightmares
PropranololBlocks beta-1 and beta-2Tremor, physical symptoms of performance anxiety, migraine prevention
MirtazapineBlocks alpha-2, among other receptorsDepression

#When it goes wrong

  • ADHD. Guanfacine improves attention through prefrontal alpha-2 receptors, without raising transmitter levels.
  • PTSD. Overactive noradrenaline signalling is linked to hyperarousal and nightmares.
  • Dizziness as a side effect. Many antipsychotics and antidepressants also block alpha-1 receptors, which lets blood pressure fall on standing.

#Acetylcholine receptors

Acetylcholine has one receptor of each design. Nicotinic receptors are fast ion channels. Muscarinic receptors are slower G-protein receptors. The names come from the plant compounds first used to tell them apart.

#The two families

NicotinicMuscarinic
DesignIon channelG protein
SpeedMillisecondsHundreds of milliseconds and longer
TypesMuscle type; neuronal types, mainly alpha-4 beta-2 and alpha-7M1 to M5
Main sitesNerve-to-muscle junction, autonomic ganglia, brainBrain, heart, glands, gut, bladder

#Muscarinic subtypes

SubtypeG proteinWhereWhat it does
M1GqCortex, hippocampusSupports memory and attention
M2GiHeart; autoreceptor in the brainSlows the heart; brake on acetylcholine release
M3GqGlands, gut, bladder, eyeSaliva, gut movement, bladder contraction, pupil constriction
M4GiStriatumRestrains dopamine release
M5GqMidbrain dopamine neuronsLess well understood

#What they do

  • Muscle. Every voluntary movement depends on nicotinic receptors at the nerve-to-muscle junction.
  • Attention. Neuronal nicotinic receptors sit mostly on nerve terminals, where they increase the release of other transmitters.
  • Memory. M1 receptors in the hippocampus and cortex support the storing of new information.
  • Dopamine balance. M4 receptors in the striatum hold dopamine release in check.

#Medicines

MedicineActionUsed for
Xanomeline with trospiumActivates M1 and M4 in the brain; trospium blocks the effect in the bodySchizophrenia
VareniclinePartly activates alpha-4 beta-2 nicotinic receptorsSmoking cessation
Oxybutynin and related drugsBlock M3Overactive bladder
Benztropine, trihexyphenidylBlock muscarinic receptors in the brainTremor and stiffness caused by antipsychotics
Muscle relaxants used in surgeryBlock nicotinic receptors on muscleAnaesthesia

#When it goes wrong

  • Myasthenia gravis. Antibodies against muscle nicotinic receptors cause weakness that worsens with activity.
  • Anticholinergic burden. Many common medicines block muscarinic receptors as a side effect. The combined load causes dry mouth, constipation, blurred vision and, in older adults, confusion and memory problems.
  • Schizophrenia. Xanomeline with trospium, approved in 2024, is the first antipsychotic that does not act on dopamine receptors. Its effect is thought to come through M4 and M1.

#Histamine receptors

Histamine has four receptors, all G-protein receptors. Two matter in the brain: H1 keeps you awake, and H3 is the brake on histamine release.

#The four types

ReceptorG proteinWhereWhat it doesMedicines
H1GqBrain, airways, blood vessels, skinWakefulness in the brain; allergy symptoms in the bodyAntihistamines block it
H2GsStomach liningAcid releaseFamotidine blocks it
H3GiBrain, as autoreceptorSlows release of histamine and other transmittersPitolisant blocks it
H4GiImmune cellsInflammation, itchNone in routine use

#What to remember

  • Why older antihistamines sedate. Diphenhydramine and similar drugs enter the brain and block H1 there. Newer antihistamines such as cetirizine and fexofenadine reach the brain much less.
  • A common source of side effects. Several antipsychotics and antidepressants, including olanzapine, quetiapine and mirtazapine, block H1 strongly. This accounts for much of their sedation and weight gain.
  • Blocking the brake promotes waking. Pitolisant blocks the H3 autoreceptor, so histamine neurons release more. It is used for the daytime sleepiness of narcolepsy.
  • Low-dose sleep medicines. Doxepin at very low doses acts almost only on H1 and is used for insomnia.

#Opioid receptors

Opioid receptors read the body's own pain-relieving peptides: endorphins, enkephalins and dynorphins. All three types are Gi-coupled, so each one quiets the cell that carries it.

#The three types

ReceptorNatural peptideWhereWhat it does
MuEndorphins, enkephalinsSpinal cord, brainstem, thalamus, reward circuits, gutPain relief, reward, slowed breathing, slowed gut
DeltaEnkephalinsCortex, limbic areas, spinal cordPain relief, mood regulation
KappaDynorphinsLimbic areas, hypothalamus, spinal cordPain relief with low mood and unease; active during stress

#How they work

Activating an opioid receptor does two things through Gi. On the sending side it closes calcium channels, so less transmitter is released. On the receiving side it opens potassium channels, so the cell is harder to excite. In pain pathways the combined effect is that fewer pain signals pass up the spinal cord.

#What they do

  • Pain control. The brain has a descending system that turns pain signals down at the spinal cord, and it runs largely on mu receptors.
  • Reward and bonding. Mu receptors contribute to the enjoyment of food, social contact and other rewards.
  • Stress. Dynorphin acting on kappa receptors produces the low, uneasy state that follows prolonged stress.
  • Breathing and the gut. Mu receptors in the brainstem slow breathing. Mu receptors in the gut wall slow its movement.

#Medicines

MedicineActionUsed for
Opioid pain medicinesActivate mu receptorsSevere acute pain, cancer pain, palliative care
BuprenorphinePartly activates mu receptorsOpioid use disorder, pain
NaloxoneBlocks opioid receptors, fast and short-actingEmergency reversal of opioid overdose
NaltrexoneBlocks opioid receptors, long-actingAlcohol and opioid use disorders

#When it goes wrong

  • The main risk follows from the map. The same mu receptors that relieve pain also slow breathing. This is why overdose is dangerous and why naloxone saves lives.
  • Tolerance and dependence. With repeated use the receptors and the cells behind them adapt. The same dose does less, and stopping suddenly causes withdrawal.
  • Constipation. It comes from mu receptors in the gut and does not fade with tolerance.
  • Research directions. Kappa receptor blockers are being studied for depression, on the reasoning that they would relieve stress-related low mood.

#Other receptors worth knowing

Four smaller receptor systems round out the picture. Each is the target of at least one widely used medicine or everyday substance.

ReceptorDesignWhat it doesActs on it
Glycine receptorIon channel, chlorideFast inhibition in the spinal cord and brainstemNo medicine in routine use
Adenosine A1G protein, GiQuiets neurons as adenosine builds up through the dayCaffeine blocks it
Adenosine A2AG protein, GsPromotes sleep; opposes dopamine D2 in the striatumCaffeine blocks it; istradefylline blocks it in Parkinson's disease
Orexin OX1, OX2G proteinHold wakefulness stableSuvorexant, lemborexant and daridorexant block them for insomnia
Melatonin MT1, MT2G protein, GiTell the body clock that it is nightMelatonin and ramelteon activate them

#What to remember

  • Caffeine is a receptor blocker. It occupies adenosine receptors and hides the fatigue signal. With regular use the brain adds adenosine receptors, which is why habitual users need more and feel tired when they stop.
  • Two ways to treat insomnia. GABA-A medicines push the brain toward sleep by increasing inhibition. Orexin blockers remove the signal that holds wakefulness in place.
  • Melatonin is a timing signal, not a sedative. It shifts the body clock. Its effect on how fast people fall asleep is modest.

#Patterns worth remembering

Six rules summarize the whole post.

  1. The receptor decides the effect. A transmitter is only a key. Whether the cell is excited, quieted or reshaped depends on the lock.
  2. Two designs, two timescales. Ion-channel receptors carry fast information. G-protein receptors change how the cell handles that information for seconds to minutes.
  3. Three G proteins predict direction. Gs and Gq activate, Gi quiets. Knowing the G protein tells you most of what a receptor does.
  4. Autoreceptors are brakes. Most are Gi-coupled and sit on the releasing cell. Drugs that block them raise release, and drugs that activate them lower it.
  5. Side effects are other receptors. Sedation, weight gain, dry mouth and dizziness usually come from a medicine also binding H1, muscarinic or alpha-1 receptors, not from its intended target.
  6. Receptors adapt. Numbers and sensitivity shift with sustained use. This explains tolerance, delayed benefit, and why many medicines are stopped gradually.

#Side effects by receptor

Receptor blockedTypical effect
Histamine H1Drowsiness, increased appetite
MuscarinicDry mouth, constipation, blurred vision, confusion in older adults
Alpha-1 adrenergicDizziness on standing
Dopamine D2Stiffness, restlessness, raised prolactin
Serotonin 5-HT2CIncreased appetite

This table describes mechanisms. It is not treatment guidance.

#What this post leaves out

  • Coverage. The brain has several hundred receptor types. Left out here are receptors for most neuropeptides, trace amines, purines other than adenosine, and all hormone receptors.
  • Medicines only. The sections cover approved medicines. Non-medical drug use is outside the scope of this post.
  • Simplified signalling. Many receptors couple to more than one G protein, pair up with other receptors, or signal through other routes. The one-line descriptions are starting points.
  • Occupancy figures are averages. The D2 ranges come from imaging studies of groups. Individuals vary.

Nothing here is medical advice.

#Verification

This post was written from general knowledge and has not yet been checked against primary sources. Treat every figure as approximate until it is. Still to check:

  • D2 occupancy ranges for antipsychotic effect and side effects
  • GABA-A subunit roles: alpha-1 sedation, alpha-2 and alpha-3 anxiety relief, alpha-5 memory
  • G-protein coupling for each receptor in the map
  • Approval status of each medicine named
  • The 5-HT1A autoreceptor account of delayed antidepressant response
  • Trial outcomes for metabotropic glutamate receptor drugs
[Contents]

Contents

[Jump to]

Jump to a section, post or action

Membership

Built for minds that think in systems.

Computermind is for the relentlessly curious: engineers, scientists and clinicians working where computer science meets neuroscience, who understand the brain deeply or are getting there. You're judged by what you contribute, not by your credentials.

  • models
  • code
  • datasets
  • papers
  • tools

We respect your privacy. No spam, ever.

your contributionmerged.merging…
[request an invite]

Tell us who's asking.

Membership is earned by contribution, so a little context helps us read your request well.

We respect your privacy. No spam, ever.